CN102239149A - 喹啉化合物作为血管新生、人类甲硫氨酰氨肽酶、以及sirt1的抑制剂,以及治疗病症的方法 - Google Patents
喹啉化合物作为血管新生、人类甲硫氨酰氨肽酶、以及sirt1的抑制剂,以及治疗病症的方法 Download PDFInfo
- Publication number
- CN102239149A CN102239149A CN2009801489900A CN200980148990A CN102239149A CN 102239149 A CN102239149 A CN 102239149A CN 2009801489900 A CN2009801489900 A CN 2009801489900A CN 200980148990 A CN200980148990 A CN 200980148990A CN 102239149 A CN102239149 A CN 102239149A
- Authority
- CN
- China
- Prior art keywords
- substituted
- optional
- alkyl
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *Oc1cccc2c1nccc2 Chemical compound *Oc1cccc2c1nccc2 0.000 description 2
- CTQMJYWDVABFRZ-UHFFFAOYSA-N Oc(c1c2cccn1)ccc2Cl Chemical compound Oc(c1c2cccn1)ccc2Cl CTQMJYWDVABFRZ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (56)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10291908P | 2008-10-06 | 2008-10-06 | |
US61/102,919 | 2008-10-06 | ||
PCT/US2009/005475 WO2010042163A2 (en) | 2008-10-06 | 2009-10-06 | Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102239149A true CN102239149A (zh) | 2011-11-09 |
CN102239149B CN102239149B (zh) | 2015-05-13 |
Family
ID=42101131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200980148990.0A Active CN102239149B (zh) | 2008-10-06 | 2009-10-06 | 喹啉化合物作为血管新生、人类甲硫氨酰氨肽酶、以及sirt1的抑制剂,以及治疗病症的方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8729097B2 (zh) |
EP (1) | EP2350012B1 (zh) |
CN (1) | CN102239149B (zh) |
ES (1) | ES2641471T3 (zh) |
HK (1) | HK1163685A1 (zh) |
WO (1) | WO2010042163A2 (zh) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103054866A (zh) * | 2013-01-28 | 2013-04-24 | 杭州雷索药业有限公司 | 氯喔星在制备抗血管生成类药物中的应用 |
CN105228984A (zh) * | 2013-03-15 | 2016-01-06 | 爱西里斯药物技术有限公司 | 硝羟喹啉碱加成盐及其用途 |
CN105963683A (zh) * | 2016-04-12 | 2016-09-28 | 青岛市中心医院 | Sirt1在角膜神经损伤修复中的应用 |
CN108299292A (zh) * | 2018-02-13 | 2018-07-20 | 安徽工业大学 | 5,7-二溴-8-(甲氧甲氧基)-2-甲基喹啉或其药用盐在治疗乳腺癌中的应用 |
CN108864064A (zh) * | 2018-08-15 | 2018-11-23 | 翟学旭 | 含氮杂环类衍生物及其在视网膜新生血管疾病中的应用 |
CN108912116A (zh) * | 2018-08-15 | 2018-11-30 | 翟学旭 | 一种含氮杂环类衍生物及其在视网膜疾病中的应用 |
WO2020063824A1 (zh) * | 2018-09-29 | 2020-04-02 | 江苏亚虹医药科技有限公司 | 硝羟喹啉前药及其用途 |
CN111960998A (zh) * | 2020-08-03 | 2020-11-20 | 江苏亚虹医药科技有限公司 | 硝羟喹啉衍生物及其制备方法和用途 |
CN113045490A (zh) * | 2019-12-27 | 2021-06-29 | 江苏亚虹医药科技股份有限公司 | 结晶型硝羟喹啉及其制备方法和用途 |
CN113474654A (zh) * | 2018-12-04 | 2021-10-01 | 伊索普莱克西斯公司 | 用于鉴定、选择性消融和选择以及收集单细胞的系统、装置和方法 |
WO2021197338A1 (zh) * | 2020-03-30 | 2021-10-07 | 江苏亚虹医药科技股份有限公司 | 硝羟喹啉前药的晶型、含其的药物组合物及其制备方法和应用 |
CN114555059A (zh) * | 2019-12-31 | 2022-05-27 | 江苏亚虹医药科技股份有限公司 | 含硝羟喹啉的药物组合物、硝羟喹啉片剂及其制备方法和用途 |
CN114621140A (zh) * | 2020-12-10 | 2022-06-14 | 中国科学院上海药物研究所 | 芳基二氟乙酰胺化合物及其制备方法和用途 |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120004162A1 (en) | 2008-12-04 | 2012-01-05 | Vath James E | Methods of Treating an Overweight or Obese Subject |
WO2013055385A2 (en) | 2011-10-03 | 2013-04-18 | Zafgen Corporation | Methods of treating age related disorders |
US8642650B2 (en) | 2008-12-04 | 2014-02-04 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
US10472315B2 (en) * | 2009-08-05 | 2019-11-12 | The Johns Hopkins University | Inhibitors of methionine aminopeptidases and methods of treating disorders |
JP5890312B2 (ja) | 2009-10-09 | 2016-03-22 | ザフゲン,インコーポレイテッド | 肥満治療に用いられるスルホン化合物 |
US8815309B2 (en) | 2010-01-08 | 2014-08-26 | Zafgen, Inc. | Methods of treating a subject with benign prostate hyperplasia |
CA2786603C (en) | 2010-01-08 | 2018-02-20 | James E. Vath | Fumagillol type compounds and methods of making and using same |
US20130266578A1 (en) | 2010-04-07 | 2013-10-10 | Thomas E. Hughes | Methods of treating an overweight subject |
US20130210821A1 (en) * | 2010-05-27 | 2013-08-15 | James E. Vath | Methods for Treating Obesity |
MX2013000836A (es) | 2010-07-22 | 2013-09-26 | Zafgen Inc | Compuestos triciclicos y metodos para elaborar y usar los mismos. |
AU2011336785A1 (en) | 2010-11-29 | 2013-06-20 | Zafgen, Inc | Treatment of obesity using non-daily administration of 6-0-(4 - dimethylaminoethoxy) cinnamoyl fumagillol |
US9321740B2 (en) | 2011-01-26 | 2016-04-26 | Zafgen, Inc. | Tetrazole compounds and methods of making and using same |
WO2012122264A1 (en) | 2011-03-08 | 2012-09-13 | Zafgen Corporation | Oxaspiro [2.5] octane derivatives and analogs |
EP2705036B1 (en) | 2011-05-06 | 2015-08-12 | Zafgen Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
CA2835209A1 (en) | 2011-05-06 | 2012-11-15 | Zafgen, Inc. | Tricyclic pyrazole sulfonamide compounds and methods of making and using same |
US9290472B2 (en) | 2011-05-06 | 2016-03-22 | Zafgen, Inc. | Partially saturated tricyclic compounds and methods of making and using same |
AU2013209723B2 (en) | 2012-01-18 | 2016-11-24 | Zafgen, Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
AU2013209719A1 (en) | 2012-01-18 | 2014-08-07 | Zafgen, Inc. | Tricyclic sulfone compounds and methods of making and using same |
WO2013169857A1 (en) | 2012-05-08 | 2013-11-14 | Zafgen, Inc. | Treating hypothalamic obesity with metap2 inhibitors |
AU2013259620B2 (en) | 2012-05-09 | 2017-05-18 | Zafgen, Inc. | Fumigillol type compounds and methods of making and using same |
US20150150869A1 (en) | 2012-06-20 | 2015-06-04 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
SG11201503521QA (en) | 2012-11-05 | 2015-06-29 | Zafgen Inc | Methods of treating liver diseases |
WO2014071369A1 (en) | 2012-11-05 | 2014-05-08 | Zafgen, Inc. | Tricyclic compounds for use in the treatment and/or control of obesity |
BR112015010225A2 (pt) | 2012-11-05 | 2017-07-11 | Zafgen Inc | compostos tricíclicos e seus métodos de produção e utilização |
EP2922544B1 (en) | 2012-11-21 | 2018-08-01 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
CN105228610A (zh) | 2013-03-14 | 2016-01-06 | 扎夫根股份有限公司 | 治疗肾疾病和其它病症的方法 |
JP6153179B2 (ja) * | 2013-04-02 | 2017-06-28 | アンジー ファーマスーティカル シーオー.,エルティーディー.Annji Pharmaceutical Co., Ltd. | 抗神経変性剤としての多機能キノリン誘導体 |
WO2015017788A1 (en) | 2013-08-01 | 2015-02-05 | Eutropics Pharmaceuticals, Inc. | Method for predicting cancer sensitivity |
US9987280B2 (en) * | 2013-08-09 | 2018-06-05 | City Of Hope | SIRT1 inhibitors and stem cell rejuvenation |
AU2014342269B2 (en) | 2013-10-30 | 2020-02-27 | Eutropics Pharmaceuticals, Inc. | Methods for determining chemosensitivity and chemotoxicity |
HUP1500098A2 (hu) * | 2015-03-09 | 2016-09-28 | Avidin Kft | 8-hidroxikinolin származékok új enantiomerjei és szintézisük |
AR105671A1 (es) | 2015-08-11 | 2017-10-25 | Zafgen Inc | Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso |
CN106432255A (zh) | 2015-08-11 | 2017-02-22 | 扎夫根公司 | 烟曲霉素醇螺环化合物和制备和使用其的方法 |
US11324739B2 (en) * | 2016-03-31 | 2022-05-10 | Jiangsu Yahong Meditech Co., Ltd. | Combinational uses of nitroxoline and its analogues with chemotherapies and immunotherapies in the treatment of cancers |
HUP1600234A2 (en) | 2016-04-05 | 2017-12-28 | Mta Termeszettudomanyi Kutatokoezpont | Mdr-reversing 8-hydroxy-quinoline derivatives |
EP3388419A1 (en) * | 2017-04-12 | 2018-10-17 | Leadiant Biosciences SA | Gli1 inhibitors and uses thereof |
GB202116743D0 (en) * | 2021-11-19 | 2022-01-05 | Healx Ltd | Treatment |
GB202218460D0 (en) * | 2022-12-08 | 2023-01-25 | Healx Ltd | Treatment |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3351525A (en) * | 1962-05-11 | 1967-11-07 | Geigy Ag J R | Coccidiostatic compositions and methods of using same |
US4758264A (en) * | 1982-02-17 | 1988-07-19 | Ciba-Geigy Corporation | Use of quinoline derivatives for the protection of cultivated plants |
US4829072A (en) * | 1986-06-27 | 1989-05-09 | Basf Aktiengesellschaft | Quinoline derivatives microbicides containing these compounds, and their use for controlling bacteria and fungi |
JPH0597674A (ja) * | 1991-10-01 | 1993-04-20 | Nikko Kyodo Co Ltd | コラーゲナーゼ阻害剤 |
US5380852A (en) * | 1990-12-21 | 1995-01-10 | Hoechst Aktiengesellschaft | 5-chloroquinolin-8-oxyalkanecarboxylic acid derivatives, useful as antidotes for herbicides |
CN1382124A (zh) * | 1999-08-27 | 2002-11-27 | 利甘德药品公司 | 二环类雄激素和孕甾酮受体调节化合物和方法 |
CN1568314A (zh) * | 2000-06-28 | 2005-01-19 | 辛根塔参与股份公司 | 制备喹啉衍生物的方法 |
WO2007086663A1 (en) * | 2006-01-24 | 2007-08-02 | University Of Seoul Foundation Of Industrial And Academic Cooperation | Hif-1 alpha activating agent |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3870790A (en) | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
US4226859A (en) | 1979-06-07 | 1980-10-07 | Velsicol Chemical Corporation | Pyridyl esters of N-alkylidene-substituted phosphor- and phosphonamidic acids |
ZA825384B (en) | 1981-07-31 | 1983-05-25 | Tillott J B Ltd | Orally administrable pharmaceutical compositions |
US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
EP0188040B1 (en) | 1985-01-11 | 1991-08-14 | Abbott Laboratories Limited | Slow release solid preparation |
JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
DE69533180T2 (de) | 1994-12-22 | 2005-07-14 | Ligand Pharmaceuticals, Inc., San Diego | Steroidrezeptor-Modulator Verbindungen und Methoden |
US5705190A (en) | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
US7846919B2 (en) * | 1998-02-10 | 2010-12-07 | Dermex Pharmaceuticals, Llc | Chelated 8-hydroxyquinoline and use thereof in a method of treating epithelial lesions |
UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
KR100501022B1 (ko) | 1998-07-28 | 2005-07-18 | 다나베 세이야꾸 가부시키가이샤 | 장내 적소 방출형 제제 |
US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
TWI328009B (en) * | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
CA2554716A1 (en) * | 2004-01-22 | 2005-08-04 | Nitromed, Inc. | Nitrosated and/or nitrosylated compounds, compositions and methods of use |
MX2007000142A (es) * | 2004-06-30 | 2007-03-26 | Combinatorx Inc | Metodos y reactivos para el tratamiento de desordenes metabolicos. |
BRPI0516830A (pt) * | 2004-10-01 | 2008-09-23 | Ramscor Inc | composições de droga de liberação sustentada convenientemente implantáveis |
US20060167044A1 (en) * | 2004-12-20 | 2006-07-27 | Arnaiz Damian O | Piperidine derivatives and their use as anti-inflammatory agents |
WO2006117660A2 (en) * | 2005-05-04 | 2006-11-09 | Clio Pharmaceutical Corporation | Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc- and/or copper dependent proteins |
US20090105202A1 (en) * | 2005-10-20 | 2009-04-23 | California Pacific Medical Center | Androsterone Derivatives and Method of Use thereof |
US20100150844A1 (en) | 2006-07-28 | 2010-06-17 | The Johns Hopkins University | Use of 8-quinolinol and its analogs to target cancer stem cells |
CA2726537A1 (en) * | 2008-06-06 | 2009-12-10 | University Health Network | 8-hydroxyquinoline derivatives for the treatment of hematological malignancies |
-
2009
- 2009-10-06 US US13/122,876 patent/US8729097B2/en active Active
- 2009-10-06 CN CN200980148990.0A patent/CN102239149B/zh active Active
- 2009-10-06 ES ES09819542.3T patent/ES2641471T3/es active Active
- 2009-10-06 EP EP09819542.3A patent/EP2350012B1/en active Active
- 2009-10-06 WO PCT/US2009/005475 patent/WO2010042163A2/en active Application Filing
-
2012
- 2012-05-04 HK HK12104371.7A patent/HK1163685A1/zh unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3351525A (en) * | 1962-05-11 | 1967-11-07 | Geigy Ag J R | Coccidiostatic compositions and methods of using same |
US4758264A (en) * | 1982-02-17 | 1988-07-19 | Ciba-Geigy Corporation | Use of quinoline derivatives for the protection of cultivated plants |
US4829072A (en) * | 1986-06-27 | 1989-05-09 | Basf Aktiengesellschaft | Quinoline derivatives microbicides containing these compounds, and their use for controlling bacteria and fungi |
US5380852A (en) * | 1990-12-21 | 1995-01-10 | Hoechst Aktiengesellschaft | 5-chloroquinolin-8-oxyalkanecarboxylic acid derivatives, useful as antidotes for herbicides |
JPH0597674A (ja) * | 1991-10-01 | 1993-04-20 | Nikko Kyodo Co Ltd | コラーゲナーゼ阻害剤 |
CN1382124A (zh) * | 1999-08-27 | 2002-11-27 | 利甘德药品公司 | 二环类雄激素和孕甾酮受体调节化合物和方法 |
CN1568314A (zh) * | 2000-06-28 | 2005-01-19 | 辛根塔参与股份公司 | 制备喹啉衍生物的方法 |
WO2007086663A1 (en) * | 2006-01-24 | 2007-08-02 | University Of Seoul Foundation Of Industrial And Academic Cooperation | Hif-1 alpha activating agent |
Non-Patent Citations (1)
Title |
---|
ROBERT MUSIOL, ET AL: "Investigating biological activity spectrum for novel quinoline analogues", 《BIOORGANIC & MEDICINAL CHEMISTRY》 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103054866A (zh) * | 2013-01-28 | 2013-04-24 | 杭州雷索药业有限公司 | 氯喔星在制备抗血管生成类药物中的应用 |
CN105228984A (zh) * | 2013-03-15 | 2016-01-06 | 爱西里斯药物技术有限公司 | 硝羟喹啉碱加成盐及其用途 |
CN105228984B (zh) * | 2013-03-15 | 2018-03-23 | 爱西里斯药物技术有限公司 | 硝羟喹啉碱加成盐及其用途 |
CN105963683A (zh) * | 2016-04-12 | 2016-09-28 | 青岛市中心医院 | Sirt1在角膜神经损伤修复中的应用 |
CN108299292A (zh) * | 2018-02-13 | 2018-07-20 | 安徽工业大学 | 5,7-二溴-8-(甲氧甲氧基)-2-甲基喹啉或其药用盐在治疗乳腺癌中的应用 |
CN108299292B (zh) * | 2018-02-13 | 2021-03-26 | 安徽工业大学 | 5,7-二溴-8-(甲氧甲氧基)-2-甲基喹啉或其药用盐在治疗乳腺癌中的应用 |
CN108864064A (zh) * | 2018-08-15 | 2018-11-23 | 翟学旭 | 含氮杂环类衍生物及其在视网膜新生血管疾病中的应用 |
CN108912116A (zh) * | 2018-08-15 | 2018-11-30 | 翟学旭 | 一种含氮杂环类衍生物及其在视网膜疾病中的应用 |
WO2020063824A1 (zh) * | 2018-09-29 | 2020-04-02 | 江苏亚虹医药科技有限公司 | 硝羟喹啉前药及其用途 |
CN113474654A (zh) * | 2018-12-04 | 2021-10-01 | 伊索普莱克西斯公司 | 用于鉴定、选择性消融和选择以及收集单细胞的系统、装置和方法 |
CN113045490A (zh) * | 2019-12-27 | 2021-06-29 | 江苏亚虹医药科技股份有限公司 | 结晶型硝羟喹啉及其制备方法和用途 |
CN114555059A (zh) * | 2019-12-31 | 2022-05-27 | 江苏亚虹医药科技股份有限公司 | 含硝羟喹啉的药物组合物、硝羟喹啉片剂及其制备方法和用途 |
WO2021197338A1 (zh) * | 2020-03-30 | 2021-10-07 | 江苏亚虹医药科技股份有限公司 | 硝羟喹啉前药的晶型、含其的药物组合物及其制备方法和应用 |
CN115427397A (zh) * | 2020-03-30 | 2022-12-02 | 江苏亚虹医药科技股份有限公司 | 硝羟喹啉前药的晶型、含其的药物组合物及其制备方法和应用 |
CN115427397B (zh) * | 2020-03-30 | 2024-01-26 | 江苏亚虹医药科技股份有限公司 | 硝羟喹啉前药的晶型、含其的药物组合物及其制备方法和应用 |
CN111960998A (zh) * | 2020-08-03 | 2020-11-20 | 江苏亚虹医药科技有限公司 | 硝羟喹啉衍生物及其制备方法和用途 |
CN115867540A (zh) * | 2020-08-03 | 2023-03-28 | 江苏亚虹医药科技股份有限公司 | 硝羟喹啉衍生物及其制备方法和用途 |
CN114621140A (zh) * | 2020-12-10 | 2022-06-14 | 中国科学院上海药物研究所 | 芳基二氟乙酰胺化合物及其制备方法和用途 |
CN114621140B (zh) * | 2020-12-10 | 2023-08-11 | 中国科学院上海药物研究所 | 芳基二氟乙酰胺化合物及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
EP2350012B1 (en) | 2017-06-28 |
HK1163685A1 (zh) | 2012-09-14 |
US8729097B2 (en) | 2014-05-20 |
ES2641471T3 (es) | 2017-11-10 |
EP2350012A4 (en) | 2012-10-24 |
CN102239149B (zh) | 2015-05-13 |
US20110301163A1 (en) | 2011-12-08 |
EP2350012A2 (en) | 2011-08-03 |
WO2010042163A2 (en) | 2010-04-15 |
WO2010042163A3 (en) | 2010-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102239149B (zh) | 喹啉化合物作为血管新生、人类甲硫氨酰氨肽酶、以及sirt1的抑制剂,以及治疗病症的方法 | |
EP1797874B1 (en) | Vascular embolus of paclitaxel-sodium alginate microsphere and its preparation | |
CN102164888A (zh) | 脱乙酰酶抑制剂和其用途 | |
CN106565686B (zh) | 微管蛋白抑制剂 | |
Wen et al. | Targeted delivery of phycocyanin for the prevention of colon cancer using electrospun fibers | |
CN104520268A (zh) | Ssao的取代的3-卤代烯丙基胺抑制剂及其用途 | |
MXPA03010528A (es) | Metodos para inhibir angiogenesis. | |
CN108883088A (zh) | 利用色酮衍生物的上皮间质转化抑制活性的作为纤维化预防及治疗用药剂学组合物的新用途 | |
CN104710337A (zh) | 异硫氰酸酯类化合物及其应用 | |
CN107438613A (zh) | 用于预防或治疗感觉毛细胞死亡的化合物和方法 | |
Maleki et al. | Silibinin exerts anti-cancer activity on human ovarian cancer cells by increasing apoptosis and inhibiting epithelial-mesenchymal transition (EMT) | |
CN107412196A (zh) | 奥利司他纳米微球及其制备方法和在抗肿瘤药物中的应用 | |
CN115054585A (zh) | 含有枸橼酸爱地那非的片剂及其制备方法和用途 | |
ES2279157T3 (es) | Extracto con actividad antitumoral y antivenenosa. | |
CN107903185B (zh) | 新型eEF2K抑制剂的制备及应用 | |
CN108349924A (zh) | 苯磺酰氨基-苯并呋喃衍生物及其用途 | |
US10632100B2 (en) | Application of obacunone in preparation of drug for preventing and treating lung damage and pulmonary fibrosis | |
CN104311519A (zh) | 具有胃黏膜损伤保护作用的功能性食品因子制备及其应用 | |
WO2019091183A1 (zh) | Yd1701在制备治疗aldh1a3高表达肿瘤的药物中的应用 | |
CN105121447B (zh) | 长春碱类衍生物及其制备方法和应用 | |
CN104161765A (zh) | 桔梗皂苷d在制备抑制血管生成药物中的应用 | |
CN101181261A (zh) | 杨梅素在制备尿酸转运子urat1抑制药物中的应用 | |
US20200222485A1 (en) | Medicinal ambrosia plant extracts | |
CN113521078A (zh) | 一种老化细胞杀伤剂及其应用 | |
CN105560302A (zh) | 老鹳草水提物在制备抗血管生成类药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1163685 Country of ref document: HK |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20111109 Assignee: Jiangsu Ya Hong Pharmaceutical Technology Co., Ltd Assignor: The Johns Hopkins University Contract record no.: 2014990000425 Denomination of invention: Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders License type: Exclusive License Record date: 20140618 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1163685 Country of ref document: HK |